Increased mortality associated with HTLV-II infection in blood donors: A prospective cohort study

Retrovirology

Volumn 1, Issue , 2004, Pages

  Orland, Jennie R ^a   Wang, Baoguang ^b   Wright, David J ^b   Nass, Catharie C ^c   Garratty, George ^c   Smith, James W ^d   Newman, Bruce ^c   Smith, Donna M ^b   Murphy, Edward L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WESTAT   (United States)

^c AMERICAN RED CROSS BLOOD SERVICES   (United States)

^d Oklahoma Blood Institute   (United States)

Author keywords

Blood donors; HTLV 1 infections; HTLV II infections; Human T lymphotropic virus; Human T lymphotropic virus 2; Mortality

Indexed keywords

ACADEMIC ACHIEVEMENT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ANAMNESIS; ARTICLE; BLOOD BANK; BLOOD DONOR; CAUSE OF DEATH; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEALTH STATUS; HEPATITIS C; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONBIOLOGICAL MODEL; NONHUMAN; PATIENT COUNSELING; PROSPECTIVE STUDY; RISK ASSESSMENT; SERODIAGNOSIS; SEX RATIO; SMOKING HABIT; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE; UNITED STATES; VIRUS PATHOGENESIS; GEOGRAPHY; STATISTICS;

BLOOD DONORS; COHORT STUDIES; GEOGRAPHY; HTLV-I INFECTIONS; HTLV-II INFECTIONS; HUMANS; PROSPECTIVE STUDIES; UNITED STATES;

EID: 4344578077     PISSN: 17424690     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-4690-1-4     Document Type: Article

References (29)

1. Manns A, Hisada M, La Grenade L: Human T-lymphotropic virus type I infection. Lancet 1999, 353:1951-1958.
2. Murphy EL, Fridey J, Smith JW, Engstrom J, Sacher RA, Miller K, Gibble J, Stevens J, Thomson R, Hansma D, Kaplan J, Khabbaz R, Nemo G: HTLV-associated myelopathy in a cohort of HTLV-I and HTLV-II-infected blood donors. The REDS investigators. Neurology 1997, 48:315-320.
3. Modahl LE, Young KC, Varney KF, Khayam-Bashi H, Murphy EL: Are HTLV-II-seropositive injection drug users at increased risk of bacterial pneumonia, abscess, and lymphadenopathy? J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:169-175.
4. Murphy EL, Glynn SA, Fridey J, Sacher RA, Smith JW, Wright DJ, Newman B, Gibble JW, Ameti DI, Nass CC, Schreiber GB, Nemo GJ: Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J Infect Dis 1997, 176:1468-1475.
5. Murphy EL, Glynn SA, Fridey J, Smith JW, Sacher RA, Nass CC, Ownby HE, Wright DJ, Nemo GJ: Increased incidence of infectious diseases during prospective follow-up of human T-lymphotropic virus type II- and I-infected blood donors. Retrovirus Epidemiology Donor Study. Arch Intern Med 1999, 159:1485-1491.
6. Lechat MF, Shrager DI, Declercq E, Bertrand F, Blattner WA, Blumberg BS: Decreased survival of HTLV-I carriers in leprosy patients from the Democratic Republic of the Congo: a historical prospective study. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 15:387-390.
7. Arisawa K, Soda M, Akahoshi M, Matsuo T, Nakashima E, Tomonaga M, Saito H: Human T-lymphotropic virus type-I infection, antibody titers and cause-specific mortality among atomic-bomb survivors. Jpn J Cancer Res 1998, 89:797-805.
8. Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, Mueller N: A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000, 181:35-41.
9. Giacomo M, Franco EG, Claudio C, Carlo C, Anna DA, Anna D, Franco F: Human T-cell leukemia virus type II infection among high risk groups and its influence on HIV-1 disease progression. Eur J Epidemiol 1995, 11:527-533.
10. Hershow RC, Galai N, Fukuda K, Graber J, Vlahov D, Rezza G, Klein RS, Des Jarlais DC, Vitek C, Khabbaz R, Freels S, Zuckerman R, Pezzotti P, Kaplan JE: An international collaborative study of the effects of coinfection with human T-lymphotropic virus type II on human immunodeficiency virus type 1 disease progression in injection drug users. J Infect Dis 1996, 174:309-317.
11. Visconti A, Visconti L, Bellocco R, Binkin N, Colucci G, Vernocchi L, Amendola M, Ciaci D: HTLV-II/HIV-1 coinfection and risk for progression to AIDS among intravenous drug users. J Acquir Immune Defic Syndr 1993, 6:1228-1237.
12. Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels EA: Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. Aids 2001, 15:1295-1302.
13. van Haastrecht HJ, van Ameijden EJ, van den Hoek JA, Mientjes GH, Bax JS, Coutinho RA: Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol 1996, 143:380-391.
14. Khabbaz RF, Onorato IM, Cannon RO, Hartley TM, Roberts B, Hosein B, Kaplan JE: Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med 1992, 326:375-380.
15. Schreiber GB, Murphy EL, Horton JA, Wright DJ, Garfein R, Chien HC, Nass CC: Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and -II) in blood donors: the Retrovirus Epidemiology Donor Study. NHLBI Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:263-271.
16. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, et al.: Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992, 327:1906-1911.
17. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo RP, Goodman ZD, Knodell RG, Gitnick G, Morgan TR, Schiff ER, Lasky S, Stevens C, Vlahcevic RZ, Weinshel E, Tanwandee T, Lin HJ, Barbosa L: Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001, 33:455-463.
18. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW, et al.: Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996, 334:1691-1696.
19. Yoshida M, Miyoshi I, Hinuma Y: Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A 1982, 79:2031-2035.
20. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G: Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985, 2:407-410.
21. Gebretsadik T, Murphy EL: Counseling and medical evaluation of HTLV-I- and HTLV-II-infected patients. AIDS Clin Rev 1993, 19-41.
22. Nagai M, Jacobson S: Immunopathogenesis of human T cell lymphotropic virus type I-associated myelopathy. Curr Opin Neurol 2001, 14:381-386.
23. Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, Pardoll DM, Jacobson S, Schneck JP: Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A 1998, 95:7568-7573.
24. Manns A, Miley WJ, Wilks RJ, Morgan OS, Hanchard B, Wharfe G, Cranston B, Maloney E, Welles SL, Blattner WA, Waters D: Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 1999, 180:1487-1493.
25. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, Hashiguchi S, Ichinose M, Bangham CR, Izumo S, Osame M: Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998, 4:586-593.
26. Orland JR, Engstrom J, Fridey J, Sacher RA, Smith JW, Nass C, Garratty G, Newman B, Smith D, Wang B, Murphy EL, HTVL Outcomes Study: Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology 2003, 61:1588-1594.
27. Ariyoshi K, Berry N, Cham F, Jaffar S, Schim van der Loeff M, Jobe O, N'Gom PT, Larsen O, Andersson S, Aaby P, Whittle H: Quantification of Human T-lymphotropic virus type I (HTLV-I) provirus load in a rural West African population: no enhancement of human immunodeficiency virus type 2 pathogenesis, but HTLV-I provirus load relates to mortality. J Infect Dis 2003, 188:1648-1651.
28. Busch MP, Laycock M, Kleinman SH, Wages J. W., Jr., Calabro M, Kaplan JE, Khabbaz RF, Hollingsworth CG: Accuracy of supplementary serologic testing for human T-lymphotropic virus types I and II in US blood donors. Retrovirus Epidemiology Donor Study. Blood 1994, 83:1143-1148.
29. Center for Disease Control and Prevention: . National Vital Statistics Reports 2003, 51:7.